-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Kura Oncology, Maintains $36 Price Target

Benzinga·06/20/2025 12:53:55
Listen to the news
Wedbush analyst Robert Driscoll reiterates Kura Oncology (NASDAQ:KURA) with a Outperform and maintains $36 price target.